Literature DB >> 12200393

Prolongation of cardiac repolarization by arsenic trioxide.

Chern-En Chiang1, Hsiang-Ning Luk, Tsui-Ming Wang, Philip Yu-An Ding.   

Abstract

Arsenic trioxide (As(2)O(3); ATO) has recently been found to be very effective for relapsed acute promyelocytic leukemia. Several articles reported prolongation of QT interval or ventricular arrhythmias in patients receiving ATO. However, the QT-prolonging effect has not been confirmed and the direct membrane effect of ATO has never been studied. In the present investigation, using conventional action potential recording technique, we found that ATO dose dependently prolonged action potential duration (APD) in guinea pig papillary muscle with a slow pacing frequency. Parenteral administration of ATO prolonged QT interval and APD in guinea pig hearts. Intravenous infusion of clinically relevant doses of ATO prolonged QT interval and APD dose dependently. These studies suggest that ATO has a direct effect on cardiac repolarization. Patients who are receiving ATO should avoid concomitant administration of other QT-prolonging agents or conditions in favor of delaying cardiac repolarization.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12200393     DOI: 10.1182/blood-2002-02-0598

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  13 in total

1.  Oxidative inactivation of the lipid phosphatase phosphatase and tensin homolog on chromosome ten (PTEN) as a novel mechanism of acquired long QT syndrome.

Authors:  Xiaoping Wan; Adrienne T Dennis; Carlos Obejero-Paz; Jeffrey L Overholt; Jorge Heredia-Moya; Kenneth L Kirk; Eckhard Ficker
Journal:  J Biol Chem       Date:  2010-11-20       Impact factor: 5.157

Review 2.  Cancer chemotherapy and cardiac arrhythmias: a review.

Authors:  Juan Tamargo; Ricardo Caballero; Eva Delpón
Journal:  Drug Saf       Date:  2015-02       Impact factor: 5.606

Review 3.  Beyond Anthracyclines: Preemptive Management of Cardiovascular Toxicity in the Era of Targeted Agents for Hematologic Malignancies.

Authors:  Tarsheen K Sethi; Basak Basdag; Nirmanmoh Bhatia; Javid Moslehi; Nishitha M Reddy
Journal:  Curr Hematol Malig Rep       Date:  2017-06       Impact factor: 3.952

4.  Association between low-level environmental arsenic exposure and QT interval duration in a general population study.

Authors:  Irina Mordukhovich; Robert O Wright; Chitra Amarasiriwardena; Emmanuel Baja; Andrea Baccarelli; Helen Suh; David Sparrow; Pantel Vokonas; Joel Schwartz
Journal:  Am J Epidemiol       Date:  2009-08-21       Impact factor: 4.897

5.  Resveratrol protects against arsenic trioxide-induced cardiotoxicity in vitro and in vivo.

Authors:  X-Y Zhao; G-Y Li; Y Liu; L-M Chai; J-X Chen; Y Zhang; Z-M Du; Y-J Lu; B-F Yang
Journal:  Br J Pharmacol       Date:  2008-03-10       Impact factor: 8.739

6.  Reduced arsenic clearance and increased toxicity in aquaglyceroporin-9-null mice.

Authors:  Jennifer M Carbrey; Linhua Song; Yao Zhou; Masafumi Yoshinaga; Aleksandra Rojek; Yiding Wang; Yangjian Liu; Heidi L Lujan; Stephen E DiCarlo; Søren Nielsen; Barry P Rosen; Peter Agre; Rita Mukhopadhyay
Journal:  Proc Natl Acad Sci U S A       Date:  2009-09-08       Impact factor: 11.205

7.  Arsenic Trioxide Consolidation Allows Anthracycline Dose Reduction for Pediatric Patients With Acute Promyelocytic Leukemia: Report From the Children's Oncology Group Phase III Historically Controlled Trial AAML0631.

Authors:  Matthew A Kutny; Todd A Alonzo; Robert B Gerbing; Yi-Cheng Wang; Susana C Raimondi; Betsy A Hirsch; Cecilia H Fu; Soheil Meshinchi; Alan S Gamis; James H Feusner; John J Gregory
Journal:  J Clin Oncol       Date:  2017-08-02       Impact factor: 44.544

Review 8.  Current first- and second-line treatment options in acute promyelocytic leukemia.

Authors:  Fulvio Massaro; Matteo Molica; Massimo Breccia
Journal:  Int J Hematol Oncol       Date:  2017-02-02

9.  In-vitro relationship between protein-binding and free drug concentrations of a water-soluble selective beta-adrenoreceptor antagonist (atenolol) and its interaction with arsenic.

Authors:  M A Alam; M A Awal; N Subhan; M Mostofa
Journal:  J Health Popul Nutr       Date:  2009-02       Impact factor: 2.000

10.  Arsenic exposure from drinking water and QT-interval prolongation: results from the Health Effects of Arsenic Longitudinal Study.

Authors:  Yu Chen; Fen Wu; Faruque Parvez; Alauddin Ahmed; Mahbub Eunus; Tyler R McClintock; Tazul Islam Patwary; Tariqul Islam; Anajan Kumar Ghosal; Shahidul Islam; Rabiul Hasan; Diane Levy; Golam Sarwar; Vesna Slavkovich; Alexander van Geen; Joseph H Graziano; Habibul Ahsan
Journal:  Environ Health Perspect       Date:  2013-02-05       Impact factor: 9.031

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.